Last ¥5,888 JPY
Change Today +296.00 / 5.29%
Volume 4.5M
4523 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 1:00 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

eisai co ltd (4523) Snapshot

Open
¥5,636
Previous Close
¥5,592
Day High
¥6,008
Day Low
¥5,530
52 Week High
01/30/15 - ¥6,008
52 Week Low
02/6/14 - ¥3,694
Market Cap
1.7T
Average Volume 10 Days
1.9M
EPS TTM
¥140.89
Shares Outstanding
296.6M
EX-Date
03/27/15
P/E TM
41.8x
Dividend
¥150.00
Dividend Yield
2.55%
Current Stock Chart for EISAI CO LTD (4523)

Related News

No related news articles were found.

eisai co ltd (4523) Related Businessweek News

No Related Businessweek News Found

eisai co ltd (4523) Details

Eisai Co., Ltd. manufactures and sells pharmaceutical products worldwide. The company offers oncology-related products, such as Halaven, an anticancer agent; Aloxi, an antiemetic agent; and Fragmin, an injectable anticlotting agent, as well as Symbenda/Treakisym, a treatment for low-grade non-Hodgkin's lymphoma and other types of lymphatic cancer. It also provides Aricept, an anti-Alzheimer's agent; Pariet/AcipHex, a proton-pump inhibitor; and Humira, a human anti-TNF-a monoclonal antibody. In addition, the company offers epilepsy products comprising Zonegran, Zebinix, and Fycompa, which are antiepileptic agents; and Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome, as well as consumer healthcare (over-the-counter) products, which include vitamin B2 preparation Chocola BB Plus. Further, it provides Methycobal, a peripheral neuropathy treatment; Warfarin, an oral anticoagulant; Actonel, an osteoporosis treatment; Selbex for the treatment of gastritis/gastric ulcer; BELVIQ, an antiobesity agent; Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment; Lyrica, a treatment for postherpetic neuralgia; and Lunesta, a treatment for insomnia. Additionally, the company is involved in the research and development of various products under the areas of oncology, vascular and immunological reaction, gastrointestinal and hepatic disorders, and neurology. It has strategic partnerships with Quintiles Inc.; SFJ Pharma Ltd.; Biogen Idec, Inc.; BioArctic Neuroscience AB; FORMA Therapeutics, Inc.; Epizyme, Inc.; PRISM BioLab Co., Ltd.; and Verastem, Inc. for the discovery and development of various products. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

10,419 Employees
Last Reported Date: 06/20/14
Founded in 1941

eisai co ltd (4523) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

eisai co ltd (4523) Key Developments

Eisai Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2015; Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2014; Revises Earnings Guidance for the Year Ending March 31, 2015

Eisai Co., Ltd. provided dividend guidance for the year ending March 31, 2015. For the year, the company expects to pay year end dividend of ¥80.00 per share. The company reported consolidated earnings results for the nine months ended December 31, 2014. For the period, the company reported revenue of ¥408,479 million against ¥445,137 million a year ago. Operating profit was ¥23,828 million against ¥45,123 million a year ago. Profit before income taxes was ¥21,659 million against ¥42,155 million a year ago. Profit for the period attributable to owners of the parent was ¥36,689 million or ¥128.46 per diluted share against ¥27,761 million or ¥97.26 per diluted share a year ago. Ratio of equity attributable to owners of the parent was 55.9% against 54.0% a year ago. Net cash from operating activities was ¥41,166 million against ¥64,390 million a year ago. Purchases of property, plant and equipment was ¥9,482 million against ¥6,331 million a year ago. Purchases of intangible assets were ¥5,342 million against ¥17,040 million a year ago. For the year ending March 31, 2015, the company excepts consolidated revenue of ¥555,000 million, operating profit of ¥30,000 million, profit before income taxes of ¥27,000 million and profit for the period attributable to owners of the parent of ¥35,000 million or ¥121.97 per basic share against previous forecast of revenue of ¥566,000 million, operating profit of ¥53,000 million, profit before income taxes of ¥49,500 million and profit for the period attributable to owners of the parent of ¥35,000 million. Revenue forecast down ¥11,000 million from the previous forecast is due to factors such as greater than expected generic erosion within Japan and the slow growth of new products in the United States. Operating profit forecast is down ¥23,000 million from the previous forecast) due to factors such a decline in gross profit, proactive expenditure aimed at returning to a growth trajectory from fiscal 2015 onward as well as the influence of exchange rates. The company expects capital expenditure of ¥20.0 billion against previous forecast of ¥27.5 billion.

Eisai and Ajinomoto Pharmaceuticals Launch Branched-Chain Amino Acid Formula Livamin Oral Granules in the Philippines

Eisai Co., Ltd. and Ajinomoto Pharmaceuticals Co., Ltd. announced that LIVAMIN Oral Granules (granules of isoleucine, leucine and valine, brand name in Japan: LIVACT Granules), a branched-chain amino acid formula, was launched in the Philippines. Ajinomoto Pharmaceuticals holds the manufacturing and marketing authorization rights to LIVAMIN Oral Granules. Under a basic contract concerning the marketing rights of LIVAMIN Oral Granules in the Asia region signed in February 2009, Eisai obtained the exclusive marketing rights from Ajinomoto Pharmaceuticals to distribute the product in the Philippines as well as Hong Kong, China and Macao. In April 2014, Eisai's subsidiary HI-Eisai Pharmaceutical Inc. received approval in the Philippines for LIVAMIN Oral Granules indicated for the improvement of hypoalbuminemia in patients with decompensated hepatic cirrhosis presenting with hypoalbuminemia despite adequate dietary intake. In hepatic cirrhosis, increase of fibrous tissues in the liver as chronic hepatitis progresses leads to hardening of the liver and results in loss of normal liver function. When hepatic cirrhosis is not accompanied with clearly defined symptoms despite partial damage to liver function, it is called compensated cirrhosis. When liver function worsens and presents with symptoms such as jaundice, malaise, ascites, edema, hepatic encephalopathy, it is called decompensated cirrhosis. The cause of such symptoms associated with decompensated hepatic cirrhosis includes malnutrition or metabolic disorder resulting from hypoalbuminemia that occurs as hepatic cirrhosis progresses. LIVAMIN Oral Granules ameliorates these symptoms by increasing serum albumin levels in patients with decompensated hepatic cirrhosis. Liver cirrhosis is a serious health issue in the Philippines, with around 127,000 people estimated to have liver cirrhosis and in 2010, it is said that approximately 9,200 people died due to liver cirrhosis.

Eisai Co., Ltd., Q3 2015 Earnings Call, Jan 30, 2015

Eisai Co., Ltd., Q3 2015 Earnings Call, Jan 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4523:JP ¥5,888.00 JPY +296.00

4523 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €15.47 EUR +0.05
Ono Pharmaceutical Co Ltd ¥12,500 JPY +50.00
Salix Pharmaceuticals Ltd $134.67 USD -0.47
Santen Pharmaceutical Co Ltd ¥7,360 JPY +130.00
Synergy Health PLC 2,165 GBp -10.00
View Industry Companies
 

Industry Analysis

4523

Industry Average

Valuation 4523 Industry Range
Price/Earnings 99.9x
Price/Sales 2.8x
Price/Book 2.9x
Price/Cash Flow 103.7x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EISAI CO LTD, please visit www.eisai.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.